Patient-derived organoids for the personalized treatment of pancreatic neuroendocrine tumor with liver metastases: A case report

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 11

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

Figures (1-4)

Tables (1-1)

Sum=0

Nov 15, 2025 (publication date) through Nov 13, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Gastrointest Oncol. Nov 15, 2025; 17(11): 112385
Published online Nov 15, 2025. doi: 10.4251/wjgo.v17.i11.112385

Table 1 Changes in tumor markers before and after treatment

TACE: Transarterial chemoembolization; AFP: Alpha fetal protein; CA: Carbohydrate antigen; CEA: Carcinoembryonic antigen.

Citation: Yang XM, Sun W, He YG, Peng XH, You N, Tang YC, Zheng L, Huang XB. Patient-derived organoids for the personalized treatment of pancreatic neuroendocrine tumor with liver metastases: A case report. World J Gastrointest Oncol 2025; 17(11): 112385
URL: https://www.wjgnet.com/1948-5204/full/v17/i11/112385.htm
DOI: https://dx.doi.org/10.4251/wjgo.v17.i11.112385